AI-generated from publicly available materials.Icon has partnered with Anthropic to integrate Claude’s AI capabilities into clinical trials, aiming to enhance operational efficiency in drug development.
In a significant move to bolster its digital innovation, Icon, a contract research organization, has entered a multi-year collaboration with Anthropic. This partnership will utilize Anthropic’s Life Sciences research team to enhance Icon's agentic AI platform, Orbis. The goal is to improve site intelligence and study planning through advanced tools like OneSearch and OnePlan, which will facilitate better site selection and feasibility assessments. Additionally, the integration aims to enhance predictive intelligence for real-time enrollment risk detection and optimize trial protocol design.
Pip White, Anthropic's head for Ireland, the UK, and Northern Europe, highlighted that operational challenges, such as study enrollment bottlenecks, significantly delay clinical development. By leveraging Icon's expertise alongside Claude's capabilities, the collaboration seeks to streamline these operational hurdles. The partnership will also enable clients to access Icon’s insights via various Claude applications, further automating routine tasks within clinical trials.
This collaboration comes amid a fluctuating relationship between Anthropic and the biotech sector. Despite past challenges, including governmental restrictions, Anthropic has made strides in the healthcare space, acquiring AI startup Coefficient Bio and securing partnerships with major companies like Bristol Myers Squibb. As the relationship between biopharma and AI technology continues to evolve, this partnership could play a pivotal role in accelerating the delivery of innovative therapies to patients.